Spiriva® Respimat® (tiotropium bromide) – Expanded indication
February 16, 2017 – Boehringer Ingelheim announced the FDA approval of Spiriva Respimat (tiotropium bromide) for the long-term, once-daily, maintenance treatment of asthma in patients 6 years of age and older.
Download PDF
